Duyuru • May 04
Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2026 Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2026. Location: 169 saxony road, suite 212, california 92024, encinitas United States New Risk • Apr 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$8.53m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$29m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Duyuru • Apr 07
Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor On April 6, 2026, Kiora Pharmaceuticals, Inc. closed the transaction New Risk • Mar 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$7.43m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$6.4m net loss in 3 years). New Risk • Nov 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$8.45m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$11m net loss in 3 years). Shareholders have been diluted in the past year (22% increase in shares outstanding). New Risk • Aug 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$8.10m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$17m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). New Risk • Jun 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$20k revenue). Market cap is less than US$10m (US$8.67m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). New Risk • May 09
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: US$20k This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$20k revenue). Market cap is less than US$10m (US$9.36m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Duyuru • May 02
Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2025 Kiora Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2025. Location: 169 saxony rd., suite 212, california 92024, encinitas, United States Major Estimate Revision • Apr 01
Consensus EPS estimates fall by 20% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -US$2.50 to -US$2.99 per share. Revenue forecast of US$6.00m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income decline 0.7% next year. Consensus price target of US$18.50 unchanged from last update. Share price fell 3.6% to US$2.93 over the past week. Price Target Changed • Jan 30
Price target decreased by 39% to US$18.50 Down from US$30.33, the current price target is an average from 2 analysts. New target price is 364% above last closing price of US$3.99. Stock is down 48% over the past year. The company is forecast to post earnings per share of US$0.86 next year compared to a net loss per share of US$24.25 last year. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to US$3.91, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 19x in the Pharmaceuticals industry in the US. Total loss to shareholders of 98% over the past three years. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to US$3.90, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years. Major Estimate Revision • Nov 15
Consensus EPS estimates fall by 20% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from US$0.887 to US$0.713 per share. Revenue forecast steady at US$16.5m. Net income forecast to shrink 252% next year vs 1.1% decline forecast for Pharmaceuticals industry in the US. Consensus price target of US$30.33 unchanged from last update. Share price fell 4.8% to US$3.40 over the past week. Price Target Changed • Nov 11
Price target increased by 34% to US$40.50 Up from US$30.33, the current price target is an average from 2 analysts. New target price is 984% above last closing price of US$3.74. Stock is down 32% over the past year. The company is forecast to post earnings per share of US$1.03 next year compared to a net loss per share of US$24.25 last year. Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to US$4.04, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years. New Risk • Oct 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.83m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 37% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (269% increase in shares outstanding). Market cap is less than US$10m (US$9.83m market cap). Minor Risk Large one-off items impacting financial results. Major Estimate Revision • Aug 23
Consensus EPS estimates increase by 64%, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$16.8m to US$16.5m. EPS estimate rose from US$0.54 to US$0.887. Net income forecast to shrink 188% next year vs 1.0% growth forecast for Pharmaceuticals industry in the US . Consensus price target of US$30.33 unchanged from last update. Share price was steady at US$3.77 over the past week. New Risk • Aug 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.98m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (269% increase in shares outstanding). Market cap is less than US$10m (US$9.98m market cap). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$3.67, the stock trades at a forward P/E ratio of 64x. Average trailing P/E is 15x in the Pharmaceuticals industry in the US. Total loss to shareholders of 99% over the past three years. Duyuru • Jul 03
Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes Kiora Pharmaceuticals, Inc. announced that it has appointed Lisa Walters-Hoffert as an independent member to the Company's Board of Directors. Ms. Walters-Hoffert is a seasoned biotech executive bringing decades of experience in strategic development, governance, finance and capital markets to the Company's Board. Ms. Walters-Hoffert will serve as chair of the audit committee and as a member of the compensation committee. Concurrent with her appointment, Ken Gayron, current chair of the audit committee, will step down as a director of the Company's Board due to other work commitments. Ms. Walters-Hoffert was a co-founder of Dar Bioscience, Inc. and following the company's merger with Cerulean Pharma, Inc. in July of 2017, became Chief Financial Officer of the resulting public company. For more than 25 years, Ms. Walters-Hoffert served as an investment banker focused on small-cap public companies in the life science and technology sectors. From 2003 to 2015, Ms. Walters-Hoffert worked at Roth Capital Partners as Managing Director in the Investment Banking Division. Ms. Walters-Hoffert has also held various positions in the corporate finance and investment banking divisions of Citicorp Securities and Oppenheimer &Co, Inc. Ms. Walters-Hoffert currently serves as a director for Flux Power Holdings, Inc. and is a member of the Board of Directors of The Elementary Institute of Science. Additionally, she has served as a member of the Board of Directors of the San Diego Venture Group, as Past Chair of the UCSD Librarian's Advisory Board, and as the Past Chair of the Board of Directors of Planned Parenthood of the Pacific Southwest. Ms. Walters-Hoffert graduated magna cum laude from Duke University with a B.S. in Management Sciences. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to US$4.92, the stock trades at a forward P/E ratio of 141x. Average trailing P/E is 16x in the Pharmaceuticals industry in the US. Total loss to shareholders of 100% over the past three years. Duyuru • Mar 26
Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024 Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024, at 10:00 Pacific Standard Time. Location: 332 Encinitas Boulevard, Encinitas california United States Agenda: To consider elect two director nominees as Class III Directors; to consider approve an amendment to the Company's Restated Certificate of Incorporation to effect a reverse stock split of the shares of the Company's Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-10, with the exact ratio of, effective time of and decision to implement the reverse stock split to be determined by the Board of Directors; to consider approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock to 150,000,000; and to consider other business matters. New Risk • Feb 06
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 17x increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$18m net loss in 3 years). Market cap is less than US$100m (US$23.0m market cap). Price Target Changed • Feb 02
Price target decreased by 69% to US$3.83 Down from US$12.33, the current price target is an average from 3 analysts. New target price is 380% above last closing price of US$0.80. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$18.55 last year. New Risk • Feb 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.1m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (328% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$6.54m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years). Price Target Changed • Nov 13
Price target increased by 42% to US$17.50 Up from US$12.33, the current price target is an average from 2 analysts. New target price is 2,781% above last closing price of US$0.61. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.33 next year compared to a net loss per share of US$18.55 last year. Duyuru • Sep 22
Kiora Pharmaceuticals, Inc. Announces Board Changes September 20, 2023 (the “Effective Date”), Paul Chaney resigned as Chairman and member of the Board of Directors of Kiora Pharmaceuticals, Inc. from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date. Mr. Chaney did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In connection with Mr. Chaney’s retirement from the Board, as of the Effective Date, the Board appointed Praveen Tyle, Ph.D. as Chairman of the Board. Additionally, the Board appointed Erin Parsons as Chair of the Compensation Committee of the Board, and appointed Carmine Stengone as a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, in each case effective as of the Effective Date. New Risk • Aug 09
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 20% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.6m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 20% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$4.06m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years). Price Target Changed • Aug 09
Price target decreased by 56% to US$20.00 Down from US$45.67, the current price target is an average from 2 analysts. New target price is 3,496% above last closing price of US$0.56. Stock is down 91% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$18.55 last year. Duyuru • Aug 02
Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director Kiora Pharmaceuticals, Inc. has appointed Carmine Stengone as an independent member to the Company's board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics. With the insights gained throughout his career and most recently from his time leading Pipeline, Stengone will positively impact guidance on strategic decision-making and further clinical development plans. In addition, his extensive network in the industry will help Kiora on multiple fronts. Stengone has served as President and Chief Executive Officer and as a director of Pipeline Therapeutics since 2018. In his role as CEO of Pipeline Therapeutics, he has completed three private rounds of financing totaling) $180 million and executed a)$1 billion collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson &Johnson. He also served as Senior Vice President, Business Development for COI Pharmaceuticals (now Avalon BioVentures Accelerator), and a member of its investment committee, where he helped co-found six new biopharmaceutical companies. While with Avalon Ventures, Carmine served as President and Chief Executive Officer of Avelas Biosciences, Inc. He also served as Vice President of Corporate Development for Afraxis Holdings, Inc. and co-founder and CEO of Afraxis, Inc., a spin-out company from Afraxis Holdings. Earlier in his career, he held positions of increasing responsibility with Phenomix Corporation, Anadys Pharmaceuticals, Inc., and Johnson &Johnson. Carmine received his MBA from the Johnson Graduate School of Management at Cornell University and his M.S. and B.S degrees in chemistry from Duke University and Wake Forest University, respectively. Duyuru • Jul 23
Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market On July 18, 2023, Kiora Pharmaceuticals, Inc. received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market, LLC notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to regain compliance with the Minimum Bid Requirement. To regain compliance with the Minimum Bid Requirement, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive trading days during this 180-day compliance period, unless the Staff exercises its discretion to extend this period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). The compliance period for the Company will expire on January 15, 2024. In the event that the Company does not regain compliance within the 180-day compliance period, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would need to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the Minimum Bid Requirement, and provide written notice to the Staff of its intention to cure the deficiency during the second compliance period. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company does not meet the other listing standards, the Staff could provide notice that the Company’s common stock will become subject to delisting. In the event the Company receives notice that its common stock is being delisted, the Nasdaq Listing Rules permit the Company to appeal any such delisting determination by the Staff to a Hearings Panel. The Company intends to actively monitor the closing bid price of its common stock and is evaluating available options to regain compliance with the Minimum Bid Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Requirement or that the Company will otherwise remain in compliance with the other listing standards for The Nasdaq Capital Market. Price Target Changed • May 12
Price target increased by 39% to US$65.50 Up from US$47.00, the current price target is an average from 2 analysts. New target price is 2,573% above last closing price of US$2.45. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$2.95 next year compared to a net loss per share of US$18.55 last year. Duyuru • Feb 16
Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301 In collaboration with Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital announced that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standard treatment. Always at the forefront of full service pharmaceutical and medical device development worldwide, Accelagen's work is first and foremost about accelerating and improving the future of human health. Currently enrolling a small group of RP patients, initial tests are currently being used to determine safety and tolerability of the experimental drug, as well as assessing whether patients have improved vision by evaluating their ability to identify objects, navigate through a mobility course and other ophthalmic and quality-of-life assessments. Also, the study is evaluating how the brain activity changes, specifically looking within the areas of image processing. Duyuru • Feb 08
Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases Kiora Pharmaceuticals, Inc. announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This study will enroll approximately 120 patients in a multi-center, controlled, randomized, double-masked trial assessing the safety and efficacy of KIO-101 eye drops in patients living with autoimmune disease who have signs and symptoms of ocular surface disease. The study is expected to begin enrolling patients in Australia in the first half of 2023. KIO-101 is part of a class of non-steroidal autoimmune disease drugs called DHODH inhibitors, which reduce T-cell proliferation and ongoing proinflammatory cytokine release. Approved systemic drugs in this class, which target systemic disease, generate about $2B in annual revenue. KIO-101 has the potential to affect the local immune response in the eye responsible for the ophthalmic signs and symptoms of these autoimmune diseases. Of the autoimmune diseases that KIO-101 is targeting, the ocular manifestations are found in approximately 3.43M patients in the U.S. The Phase 2 study of KIO-101 is a multicenter, randomized, controlled, double-masked clinical trial in up to 120 patients with ocular signs and symptoms and diagnosed autoimmune diseases, including RA, psoriatic disease, systemic lupus erythematosus, or fibromyalgia. The study will evaluate two concentrations of KIO-101, 0.15 % and 0.30 %. The efficacy endpoints will evaluate a number of established ocular signs and symptoms, including but not limited to corneal staining and changes in the Schirmer's test score at 12 weeks. The study will also evaluate several safety and tolerability measures. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Employee Independent Director Erin Parsons was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Aug 17
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Employee Independent Director Erin Parsons was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Jan 21
No longer forecast to breakeven The 3 analysts covering Kiora Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$38.8m in 2023. New consensus forecast suggests the company will make a loss of US$17.8m in 2023. Price Target Changed • Aug 17
Price target decreased to US$11.83 Down from US$13.25, the current price target is an average from 3 analysts. New target price is 622% above last closing price of US$1.64. Stock is down 66% over the past year. Executive Departure • Aug 05
Director Steven Boyd has left the company On the 3rd of August, Steven Boyd's tenure as Director ended after 3.2 years in the role. We don't have any record of a personal shareholding under Steven's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Executive Departure • Aug 05
Director I. Maher has left the company On the 3rd of August, I. Maher's tenure as Director ended after 1.6 years in the role. We don't have any record of a personal shareholding under Maher's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Breakeven Date Change • May 14
No longer forecast to breakeven The 2 analysts covering EyeGate Pharmaceuticals no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$28.4m in 2022. New consensus forecast suggests the company will make a loss of US$3.90m in 2022. Price Target Changed • Apr 06
Price target decreased to US$13.08 Down from US$14.83, the current price target is an average from 3 analysts. New target price is 162% above last closing price of US$4.99. Stock is down 3.9% over the past year. Reported Earnings • Mar 28
Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019) Full year 2020 results: Net loss: US$8.09m (loss widened 14% from FY 2019). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 05
New 90-day high: US$7.30 The company is up 121% from its price of US$3.30 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 12
New 90-day high: US$6.63 The company is up 70% from its price of US$3.89 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. Price Target Changed • Dec 23
Price target raised to US$12.83 Up from US$11.50, the current price target is an average from 3 analysts. The new target price is 125% above the current share price of US$5.71. As of last close, the stock is down 34% over the past year. Is New 90 Day High Low • Dec 22
New 90-day high: US$5.21 The company is up 38% from its price of US$3.78 on 22 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Analyst Estimate Surprise Post Earnings • Nov 11
Earnings beat expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Is New 90 Day High Low • Oct 29
New 90-day low: US$3.57 The company is down 18% from its price of US$4.34 on 30 July 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Price Target Changed • Sep 25
Price target lowered to US$11.17 Down from US$63.75, the current price target is an average from 3 analysts. The new target price is 206% above the current share price of US$3.65. As of last close, the stock is up 16% over the past year.